Insmed logo

Insmed (INSM) Q1 2026 Earnings

INSM·Reported May 7, 2026·Before market open

Insmed reported Q1 2026 revenue of $306.0M (+229.6% YoY), beat analyst consensus of $300.8M by $5.2M. Diluted EPS came in at $-0.76 (+46.5% YoY), beat the $-0.90 consensus by $0.14. Insmed reports across 3 business segments, led by Respiratory, Immunology & Inflammation, and Neuro & Other Rare.

Revenue
$306.0Mbeat by $5.2M
Consensus: $300.8M
Diluted EPS
$-0.76beat by $0.14
Consensus: $-0.90
SEC

SEC Filings

Earnings release8-K · 0001140361-26-019430
Quarterly report10-Q · 0001104506-26-000032

Financial Snapshot

Trailing eight quarters through Q1 2026

View all metrics

Revenue

View metric

Operating Cash Flow

View metric

EPS (Diluted)

View metric

Q1 2026 Earnings FAQ

Common questions about Insmed's Q1 2026 earnings report.

Insmed (INSM) reported Q1 2026 earnings on May 7, 2026 before market open.

Insmed reported revenue of $306.0M and diluted EPS of $-0.76 for Q1 2026.

Revenue beat the consensus estimate of $300.8M by $5.2M. EPS beat the consensus estimate of $-0.90 by $0.14.

Compared to the same quarter a year prior, revenue grew 229.6% from $92.8M a year earlier and diluted EPS grew 46.5% from $-1.42.

You can read the 8-K earnings release (0001140361-26-019430) and the 10-Q periodic report (0001104506-26-000032) directly on SEC EDGAR. The filing index links above go to sec.gov.